Rationale: There is a noticeable underrepresentation of minorities in clinical trials and
registries in pulmonary arterial hypertension (PAH). Prior studies evaluating the association …

This study explores the racial and ethnic differences in presentation, severity, and treatment
of patients with pulmonary arterial hypertension (PAH) in a large multicenter registry. African …

BACKGROUND Prior research has suggested that the prevalence and outcomes of
pulmonary arterial hypertension (PAH) may vary by race or ethnicity. However, these studies …

Rationale: Limited information is available on racial/ethnic differences in pulmonary arterial
hypertension (PAH). Objectives: Determine effects of race/ethnicity and ancestry on mortality …

OBJECTIVES: Pulmonary hypertension portends a poorer prognosis for blacks versus white
populations, but the underlying reasons are poorly understood. We investigated …

Rationale: The population of patients with pulmonary arterial hypertension (PAH) has
evolved over time from predominantly young White women to an older, more racially diverse …

In the past decade and a half, the introduction of new therapeutic agents has revolutionized
the management of pulmonary arterial hypertension (PAH). These new treatment options …

While estimates of pulmonary arterial hypertension incidence and prevalence commonly
range from 1–3/million and 15–25/million, respectively, clinical experience at our institution …

Rationale: Lower socioeconomic status (SES) confers a heightened risk of common
cardiovascular and pulmonary diseases and increased mortality. The association of SES …

Background: Health disparities have a major impact in the quality of life and clinical care
received by minorities in the United States. Pulmonary arterial hypertension (PAH) is a rare …